← Eichor
Study identifier: NCT06616194 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

A Study to Learn About the Study Medicine Called Rimegepant in Adolescents With Frequent Migraine

Condition: Migraine  ·  Sponsor: Pfizer

PhasePhase 3
Planned participants200
Who can joinAll sexes, 12 Years to 17 Years
Healthy volunteersNo

About this study

The purpose of this study is to learn about the effect of a study medicine called rimegepant in adolescents who have frequent migraine attacks. Rimegepant is a tablet that dissolves when you put it on or under your tongue. The study will enroll participants who have headache for 15 days (or more) every month, of which 8 days (or more) of migraine every month, and each untreated attack lasts for an average of 4-72 hours In the 1st part of the study approximately half of the participants will receive a rimegepant tablet every other day, and approximately half of the participants will receive an inactive oral tablet (that looks the same as the rimegepant tablet) every other day. Participant experiences when they are taking the study medicine will be compared to when they are taking the inactive tablet. This will help to determine if the study medicine is safe and effective. The 1st phase of the study will last 3 months. In the 2nd part of the study all the participants who stay on study will receive rimegepant tablet every other day. This 2nd phase of the study will last 1 year. This will help determine if the study medicine is safe when taken for a long period. Those who will participate in both phases will have up to 19 visits at the study clinic, about one every 4 weeks (this may vary from 2 to 8 weeks interval during the study). Home health visits may occur as well. A health check and blood sample will be conducted at all visits. Participants will have to complete a da…

This description comes directly from the study's public registry record.

Talk to the study team

Pfizer CT.gov Call Center  ·  1-800-718-1021  ·  ClinicalTrials.gov_Inquiries@pfizer.com

Always discuss trial participation with your own doctor first.

Locations (102)

Xenoscience IncPhoenix, Arizona, United StatesRecruiting
Adult & Child Neurology Medical AssociatesLong Beach, California, United StatesRecruiting
Children's Hospital ColoradoAurora, Colorado, United StatesRecruiting
Ann & Robert H. Lurie Children's Hospital of ChicagoChicago, Illinois, United StatesRecruiting
Chicago Headache Center and Research InstituteChicago, Illinois, United StatesRecruiting
Chicago Headache Center and Research InstituteNaperville, Illinois, United StatesRecruiting
New England Regional Headache CenterWorcester, Massachusetts, United StatesRecruiting
Michigan Headache & Neurological InstituteAnn Arbor, Michigan, United StatesRecruiting
Clinvest Headlands LlcSpringfield, Missouri, United StatesRecruiting
Rutgers UniversityNew Brunswick, New Jersey, United StatesRecruiting
OnSite Clinical SolutionsCharlotte, North Carolina, United StatesRecruiting
Duke Health Center CreekstoneDurham, North Carolina, United StatesRecruiting

+ 90 more locations — full list on the registry record.

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06616194